Page 82 - CIBERES-2015-eng

Research Groups
Group 26
Programme: Pneumonia
Lead Researcher: Pérez Trallero, Emilio
Group members
STAFF MEMBERS: Esnal Lasarte, Olatz | Tamayo Oya, Esther.
ASSOCIATED MEMBERS: Alonso Asencor, Marta | Cilla Eguiluz, Carlos Gustavo | Ercibengoa Arana, María |
González Pérez Yarza, Eduardo | Marimón Ortiz de Zarate, José Ma | Montes Ros, Milagrosa | Vicente Anza, Diego.
Main lines of research
RESPIRATORY INFECTION:
Main objective: to study the epidemiology of respirato- ry infections.
Streptococcus pneumoniae infection.
• Pneumococcal invasive infection in paediatric and
adult populations: incidence, serotypes and geno-
types.
• Non-invasive pneumococcal infection: otitis media
and conjunctivitis. Serotypes and genotypes. Antibi-
otic resistance.
• Studies on vaccines. Impact of the 13 -valent conju-
gate vaccine. Comparison with the 7-valent vaccine. Influence of childhood vaccination with the new 13-valent vaccine on invasive infection and naso- pharyngeal carriage in the first years of life.
• Design of new pneumococcal typing techniques.
• Determine the evolution of S. pneumoniae antibiotic resistance over time: new serotypes causing infec- tion and genetic resistance determinants; influence of antibiotic consumption in resistance; spread of
multi-resistant clones after the introduction of con-
jugate vaccines.
• To confirm the replacement of the “resistant sero-
types” as a result of the commercialization of 13-va-
lent conjugate vaccine in 2010.
• Influence of childhood vaccination on antibiotic re-
sistance in adults.
Streptococcus pyogenes infection.
• Incidence and characterization of strains causing
invasive disease.
• Incidence and characterization of S. pyogenes strains
causing non-invasive disease: otitis, pharyngitis, and
other skin and soft tissue infections.
• S. pyogenes pneumonia. Clinical and epidemiological
aspects.
• Phenotypic and genotypic characterization of S. py-
ogenes isolates.
• Study of antibiotic susceptibility. S. pyogenes mecha-
nisms of resistance to macrolides, tetracyclines and fluoroquinolones.
82 I Annual report 2015 I CIBERES